Jenscare Exits Pre-Revenue Stage With First-Ever Sales in 2025

MT Newswires Live

Jan 26

Jenscare Scientific (HKG:9877) said it expects to generate its first-ever revenue in the year ended Dec. 31, 2025, marking its transition out of the pre-revenue stage following the commercialization of its core products.

The company expects revenue of about 90 million yuan to 92 million yuan, with other income and gains of around 15 million yuan to 18 million yuan, bringing total income to roughly 105 million yuan to 110 million yuan, according to a Monday bourse filing.

Jenscare said revenue was driven mainly by sales of its transcatheter aortic valve replacement system, Ken-Valve, in its first year on the market.

The company added that several of its structural heart interventional products have been used in paid clinical implantations overseas, contributing to revenue generation during the period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2606218295"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2606218295\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2606218295?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-26 13:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606218295","market":"fut","top_or_hot":-1,"title":"Jenscare Exits Pre-Revenue Stage With First-Ever Sales in 2025","media":"MT Newswires Live","content":"<html><body><p> Jenscare Scientific (HKG:9877) said it expects to generate its first-ever revenue in the year ended Dec. 31, 2025, marking its transition out of the pre-revenue stage following the commercialization of its core products.</p><p>The company expects revenue of about 90 million yuan to 92 million yuan, with other income and gains of around 15 million yuan to 18 million yuan, bringing total income to roughly 105 million yuan to 110 million yuan, according to a Monday bourse filing.</p><p>Jenscare said revenue was driven mainly by sales of its transcatheter aortic valve replacement system, Ken-Valve, in its first year on the market.</p><p>The company added that several of its structural heart interventional products have been used in paid clinical implantations overseas, contributing to revenue generation during the period.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jenscare Exits Pre-Revenue Stage With First-Ever Sales in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJenscare Exits Pre-Revenue Stage With First-Ever Sales in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-26 13:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Jenscare Scientific (HKG:9877) said it expects to generate its first-ever revenue in the year ended Dec. 31, 2025, marking its transition out of the pre-revenue stage following the commercialization of its core products.</p><p>The company expects revenue of about 90 million yuan to 92 million yuan, with other income and gains of around 15 million yuan to 18 million yuan, bringing total income to roughly 105 million yuan to 110 million yuan, according to a Monday bourse filing.</p><p>Jenscare said revenue was driven mainly by sales of its transcatheter aortic valve replacement system, Ken-Valve, in its first year on the market.</p><p>The company added that several of its structural heart interventional products have been used in paid clinical implantations overseas, contributing to revenue generation during the period.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSI","symbol_name":"Stage Stores Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2606218295","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606218295","pubTimestamp":1769403999,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jenscare Scientific  said it expects to generate its first-ever revenue in the year ended Dec. 31, 2025, marking its transition out of the pre-revenue stage following the commercialization of its core products.The company expects revenue of about 90 million yuan to 92 million yuan, with other income and gains of around 15 million yuan to 18 million yuan, bringing total income to roughly 105 million yuan to 110 million yuan, according to a Monday bourse filing.Jenscare said revenue was driven mainly by sales of its transcatheter aortic valve replacement system, Ken-Valve, in its first year on the market.The company added that several of its structural heart interventional products have been used in paid clinical implantations overseas, contributing to revenue generation during the period.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SSI":"Stage Stores Inc"},"translate_title":"Jenscare将于2025年实现首次销售，退出营收前阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSI":1.5},"content_text":"Jenscare Scientific (HKG:9877) said it expects to generate its first-ever revenue in the year ended Dec. 31, 2025, marking its transition out of the pre-revenue stage following the commercialization of its core products.The company expects revenue of about 90 million yuan to 92 million yuan, with other income and gains of around 15 million yuan to 18 million yuan, bringing total income to roughly 105 million yuan to 110 million yuan, according to a Monday bourse filing.Jenscare said revenue was driven mainly by sales of its transcatheter aortic valve replacement system, Ken-Valve, in its first year on the market.The company added that several of its structural heart interventional products have been used in paid clinical implantations overseas, contributing to revenue generation during the period.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}